Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | ESMO 2022: Highlights from the Presidential Symposium

Solange Peters, MD, PhD, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, provides an overview of key trials presented during the Presidential Symposium of the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France. These include a talk on air pollution induced non-small cell lung cancer in never smokers, the results of the Phase III DeFi trial (NCT03785964) of randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors as well as findings of a Phase III study (NCT02278887) evaluating tumor-infiltrating lymphocytes (TILs) in patients with advanced melanoma. This interview took place at the ESMO 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.